Efficacy of switching from teriparatide to zoledronic acid or denosumab on bone mineral density and biochemical markers of bone turnover in older patients with severe osteoporosis: a real-life study.

Endocrine · 2023 · PMC10462496 · PMID 37402061

Europe PMC DOI

hedged sentence

0.1810

closest p · 3.6× alpha

0.1810

boldest claim

The sentences

showed a trendp = 0.181not close (p > 0.1)

Sequential ZOL treatment after TPT showed a trend to increase the lumbar T-score from a mean ± SD T-score of −2.37 ± 1.33 after TPT to −2.11 ± 1.34 after ZOL treatment (Fig. 2a , p = 0.181).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.